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Abstract
The thyrotropin receptor (TSHR) is a seven transmembrane G-protein linked glycoprotein expressed on the thyroid cell
surface and which, under the regulation of TSH, controls the production and secretion of thyroid hormone from the thyroid
gland. This membrane protein is also a major target antigen in the autoimmune thyroid diseases. In Graves’ disease,
autoantibodies to the TSHR (TSHR-Abs) stimulate the TSHR to produce thyroid hormone excessively. In autoimmune
thyroid failure, some patients exhibit TSHR-Abs which block TSH action on the receptor. There have been many attempts to
generate human stimulating TSHR-mAbs, but to date, only one pathologically relevant human stimulating TSHR-mAb has
been isolated. Most mAbs to the TSHR have been derived from rodents immunized with TSHR antigen from bacteria or
insect cells. These antigens lacked the native conformation of the TSHR and the resulting mAbs were exclusively blocking or
neutral TSHR-mAbs. However, mAbs raised against intact native TSHR antigen have included stimulating mAbs. One such
stimulating mAb has demonstrated a number of differences in its regulation of TSHR post-translational processing. These
differences are likely to be reﬂective of TSHR-Abs seen in Graves’ disease.
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Thyrotropin receptor
The thyrotropin receptor (TSHR) is a G protein-
coupled receptor with a large extracellular domain.
This molecule is expressed on the surface of thyroid
follicular epithelial cells to regulate thyroid growth,
hormone production and release (Rapoport et al.
1998, Rees Smith et al. 1988, Davies et al. 2002).
A TSHR holoreceptor is expressed on the plasma
membrane (Misrahi et al. 1994, Tanaka et al. 1999)
and subsequently undergoes intramolecular cleavage,
resulting in the loss of an intervening region (TSHR
residues ,316–366). This results in a two subunit
structure, with a (or A) and b (or B) subunits held
together by disulﬁde bonds (Rapoport et al. 1998).
The conformational structure made up of the
extracellular region of the receptor is the site of TSH
binding. The extracellular a subunit (residues to
,316 after intra-molecular cleavages) is shed from the
plasma membrane in vitro (Couet et al. 1996) and
presumed to undergo the same process in vivo. The
seven transmembrane regions and cytoplasmic b
subunit (residues from ,366) of the receptor are
involved in signal transduction and are detected in
greater concentrations than the a subunits (Loosfelt
et al. 1992, Tanaka et al. 1999) due to the a subunit
shedding. In addition to this post-translational
processing, the TSHR has also been shownto undergo
homomeric multimer formation in vivo (Graves et al.
1996) and in vitro (Latif et al. 2001) and the TSH is
able to monomerize these multimeric TSHR
complexes (Latif et al. 2002).
The TSHR and thyroid autoimmunity
The TSHR is a target antigen of T cells and
autoantibodies in autoimmune thyroid disease.
These diseases include hyperthyroid Graves’ disease
(GD) and hypothyroid Hashimoto’s thyroiditis (HT).
Autoantibodies to the TSHR (TSHR-Abs) may
activate the TSHR, resulting in overproduction of
thyroid hormone, or block the thyrotropic action of
TSH, inducing thyroid atrophy and hypothyroidism
(Rees Smith et al. 1988, Davies et al. 2002).
In addition to these two classes of TSHR-Abs, there
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which bind to the TSHR without inﬂuencing TSH
binding to the TSHR or TSH action. The presence of
neutral TSHR antibodies was ﬁrst reported in a
patient with GD and monoclonal gammopathy
(Tonacchera et al. 1996). Using afﬁnity puriﬁed
TSHR, it has now been suggested that sera from
healthy normal controls may also contain neutral
TSHR-Abs (Atger et al. 1999). However, the presence
of these antibodies in healthy individuals seems to be
very rare (Metcalfe et al. 2002) and the clinical
signiﬁcance of neutral antibodies to the TSHR is
presently uncertain.
TSHR autoantibodies
TSHR-Abs detected in the sera from patients with
autoimmune thyroid disease or animals immunized
with TSHR antigen are produced from peripheral,
splenic and inﬁltrating intrathyroidal B cells (Table I).
If a repertoire of TSHR monoclonal antibodies
(mAbs) is to be generated, it should reﬂect the
antibody repertoire which is present in the patients or
immunized animals. Therefore, it is important to
know the characteristics of serum TSHR-Abs as a
reﬂection of the B cell repertoire from which they
arise.
TSHR-Abs inserafrom patientswith GD have been
shown to be oligoclonal IgG as determined by IgH
(Zakarija 1983, Weetman et al. 1990) and IgL
(Weetman et al. 1990) isotyping. Patient serum is
thought to be often a mixture of stimulating and
blocking antibodies (Kim et al. 2000, Minich et al.
2004) and probably also includes neutral TSHR
antibodies (Tonacchera etal.1996,Jaumeetal.1997).
Manyoftheseantibodiesaredetectedbytheirabilityto
displace labeled TSH binding to porcine (Rees Smith
etal.1988)orhumanTSHRs(Costagliolaetal.1999).
This activity can be found in nearly 100% of untreated
GD patients (Costagliola et al. 1999, Maugendre and
Massart 2001, Schott et al. 2004) and, in general,
decreases with treatment of the disease (Maugendre
and Massart 2001, Schott et al. 2004). This TSH
competing activity, by deﬁnition, is a reﬂection of both
stimulating and blocking antibodies although in GD
most such activity is a reﬂection of stimulators (Ando
and Davies 2005). Stimulating antibodies induce
cAMP production as a result of TSHR activation
while blocking TSHR antibodies inhibit cAMP
generation induced by TSH; thus allowing for their
easy distinction. TSHR-Abs are present in very low
concentrations in the serum of patients (,10ug/ml)
(Jaume et al. 1997, Chazenbalk et al. 1997, Atger et al.
1999, Cornelis et al. 2001) yet, in GD, are still able to
induce hyperthyroidism. Therefore, pathophysiologi-
cally relevant monoclonal stimulating and blocking
antibodies should show TSH competing activity, and
induce or inhibit cAMP production in low
concentrations.
Factors affecting the generation of rodent
mAbs to the TSHR
To obtain mAbs in a rodent, careful consideration of
the nature of the antigen is mandatory. There is a
reduced chance of inducing antibody to a confor-
mational epitope if it is not present in the antigen used
for immunization. In order to induce stimulating
TSHR-Abs by immunization, it has been found that
the TSHR antigen must be intact and not denatured
or fragmented. However, in order to induce TSHR-
Abs to short residues (linear epitope), denatured
TSHR antigen without its intact conformation has
been successful.
Similarly, the type of mAbs obtained, either human
or rodent, will depend on their detection by the
screening method used (Table II). As reviewed in
Ando and Davies (2005), stimulating antibodies
recognize conformational epitopes on the a subunit
of the TSHR. Blocking antibodies recognize either the
same or closely related conformational binding sites
that stimulating antibodies bind to, or they recognize
linear epitopes including those on the N terminus of
the b subunit of the TSHR. Therefore, if the TSHR
antigen used for screening does not have intact
conformation, then stimulating antibodies and some
Table I. TSHR antigens and mAb generation.
B cell Transformation TSHR antigen Cons and pros
Human PBMC* Mouse plasmacytoma Native TSHR in vivo
† Stimulating mAbs could potentially be obtained,
but clones tend to be unstable. Epstein bar virus Native TSHR in vivo
Animal SPC* Mouse myeloma Denatured TSHR mAbs often recognize only the denatured
antigen.
Native TSHR Antigen may not be intact at
the site of immunization.
Native TSHR in situ
‡ mAbs tend to recognize only the
native TSHR.
*PBMC— peripheral blood mononuclear cells; SPC—spleen cells.
†TSHR expressed on the thyroid gland.
‡TSHR expressed by an expression vector at the site of immunization.
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one may be able to obtain mAbs which only react with
denatured TSHR when screening is dependent on
using denatured TSHR antigen. Hence, the screening
method is the second important factor in addition to
the immunizing antigen.
Monoclonal antibodies to the TSHR
Use of peripheral B cells from GD patients
Human–mouse hybridoma formation. The ﬁrst human
TSHR-mAbsintheliteratureappearedinValenteetal.
(1982) and were generated by using mouse myeloma
cells to fuse and transform target lymphocytes from
patients with GD resulting in heterohybridomas.
Subsequently, human myeloma cells were also used
togeneratemAbs (Yoshidaet al.1988).More recently,
TSHR-mAbs were produced from a patient with HT
by using a mouse myeloma partner (Kohn et al. 1997).
These mAbs, mostly IgG, showed stimulating or
blocking activity only at high concentrations
(.100ug/ml). Binding of some of these stimulating
mAbs to thyroid membrane was signiﬁcantly inhibited
by TSH, but these mAbs did not show any TSH
competing activity themselves. Such studies clearly
indicated that the human TSHR mAbs described, and
which required .100ug/ml to see activity, were of low
afﬁnity and not likely to be present in high enough
concentrations in the serum of patients. Therefore, no
clinical signiﬁcance could be assigned to them.
EBV transformation of B cells. Epstein bar virus (EBV)
infects and transforms human B cells. This ability has
been utilized to immortalize Ab-producing B cells
from peripheral blood lymphocytes. Baker et al.
(1988) reported the result to be an IgM TSHR mAb
by using this method. This IgM mAb showed no
TSH competition but blocked TSH activity. It
reacted with 15–18kDa products on Western blots,
but the detected bands did not correspond to the
molecular weight of the TSHR, suggesting that its
blocking activity was non-speciﬁc. More recently,
after eliminating IgM bearing peripheral B cells by
negative-sorting, IgG mAbs with weak TSHR
stimulating activity (up to 3 fold stimulation of
cAMP) were isolated (Li et al. 1995). Although the
poor stimulating activity of these mAbs was
secondary to low afﬁnity binding, one was used to
generate a transgenic mouse model of GD (Kim-
Saijo et al. 2003). This mAb (B6B7) was originally
reported as IgG, but the transgenic animals carried
an IgM version of this mAb due to a class switch.
There was detectable (,50ug/ml) human IgM in the
mouse serum and in some animals this transgene
product increased serum T4 levels. However, the
maximum increase observed was a doubling in the
average level of serum thyroxine when compared to
control mice. Furthermore, ,40% of the transgenic
mice did not show any increase in T4 levels even with
detectable human IgM in the serum. Nevertheless,
despite the low potency of the TSHR mAb some of
these mice also showed thyroid hypertrophy (Kim-
Saijo et al. 2003) and this remains an interesting
model to be veriﬁed by other investigators. Recently,
a potent stimulating human IgG TSHR mAb has
been successfully isolated using this technique after
screening .16,000 wells by a TSH binding
competition assay (Sanders et al. 2003). This mAb
generated from a patient with GD showed potent
thyroid stimulating activity at low concentrations
(,2–3 times cAMP stimulation at ,1ng/ml), much
stronger than previous human mAbs. Hence, human
mAbs can be obtained from patients with GD but the
difﬁculty in selecting them is consistent with the low
levels of TSHR-Abs present (Chazenbalk et al. 1997,
Jaume et al. 1997, Atger et al. 1999, Cornelis et al.
2001) and a low frequency TSHR-Ab secreting
plasma cells.
TSHR-mAbs from animals immunized with TSHR
antigen
mAbs raised against recombinant denatured TSHR
antigen. Loosfelt et al. (1992) generated several
mAbs raised against the TSHR ectodomain and
Table II. mAb screening.
Method TSHR antigen Pros Cons
ELISA Denatured/native Ideal for mass screening. Not expensive. May not detect mAbs to native
conformation of the TSHR
Labeled TSH* Solubilized/native Detected only stimulating and blocking mAbs Miss neutral mAbs. Costly and labor
intensive. Radioisotope used.
†
Camp Native form Detects only stimulating and blocking mAbs. Miss neutral mAbs. Needs cell culture.
Costly and labor intensive. Radioisotope used
†
FACS Native form Best to detect mAbs to the
native TSHR. Not expensive
Needs cell culture and labor intensive.
May miss mAbs to the linear
epitopes.
*Labeled TSH indicates TSH binding competition assay and when this assay is performed with the native TSHR, cell culture is needed.
TSHR conformation is different between the solubilized and the native TSHR.
†Non-radioisotope kits are commercially available.
TSHR-mAbs 139transmembrane region of the TSHR. These mAbs
conﬁrmed the two subunit structure of the TSHR as
originally shown using radio labeled TSH cross-
linking (Kajita et al. 1985). These probes also
demonstrated b subunit predominance (Loosfelt
et al. 1992) which has been conﬁrmed in other
laboratories (Tanaka et al. 1999). Using two mAbs
raised against TSHR a subunit residues 19–243 but
with distinct epitopes, this group further detected
shed TSHR a subunits in the cell culture medium
(Couet et al. 1996). Such reactivity was not detected
with mAbs to the intracellular tail. However, the TSH
competing activity of the mAbs in these studies has not
been reported. Seeraramaiah et al. (1995) immunized
mice with insect-derived TSHR ectodomain and
generated 23 mAbs, including 2 mAbs with TSH
competing and blocking activity. However, this
activity was seen only in high concentrations
(.250ug/ml). These mAbs had linear epitopes
within TSHR residues 277–296. Nicholson et al.
(1996) generated 5 mAbs raised against TSHR
ectodomain produced in E. coli and insect cells.
Some of the mAbs in this study have been widely used
for studies of the TSHR. For example, their A9 mAb
recognized TSHR residues 147–229, the native
TSHR expressed in thyroid tissue and frozen
specimens (Nicholson et al. 1996) and the TSHR in
immunoprecipitation studies (Tanaka et al. 1999,
Chazenbalk et al. 2002). Their mAb A10 recognized
residues 22–35 (Nicholson et al. 1996) and has been
especially useful in immunoblot studies (Vlase et al.
1997). Davies et al. (1998) also generated 10 mAbs
raised against mouse TSHR ectodomain produced in
insect cells. These mAbs, when studied in an ELISA
format, showed preferential recognition of mouse
TSHRs over human TSHRs. Certain mAbs showed
TSH competing and blocking activity, but again only
at relatively high concentrations (.50ug/ml).
Most of the above mentioned mAbs were
generated and screened for using the same TSHR
antigen. The mAbs reacted well with the antigen
used for immunization but did not react (Seerar-
amaiah et al. 1995, Nicholson et al. 1996, Davies
et al. 1998), or reacted much less (Seeraramaiah et al.
1995, Davies et al. 1998) with the native TSHR.
However, other studies have used a more logical
approach; immunizing with the available denatured
antigen but screening with the native TSHR antigen.
Johnstone et al generated mAb 2C11 raised against
the TSHR ectodomain generated in bacteria (John-
stone et al. 1994). This antibody was obtained by
screening with CHO cells expressing the native
TSHR, and it reacted with a linear epitope of
residues 355–358 (Shepherd et al. 1999). More
mAbs were later generated by this method but all are
bound to TSHR residues 381–384 and blocked
rather than stimulated TSH induced cAMP gener-
ation (,80% blockade at ,1ug/ml). Oda et al.
(1998) took a different approach to screening by
using immunoprecipitation of radio-labeled in vitro
translated TSHR but this TSHR preparation was
shown not to be recognized by TSHR-Abs present in
GD sera (Prentice et al. 1997). One antibody (3C7),
with a linear epitope to residues 246–260, showed
TSH competing activity (.20%) but, once again,
only observed with more than ,30ug/ml and did
not recognize native TSHR expressed on CHO cells
(Oda et al. 1998).
Hence, mAbs screened by using native TSHR
preparations (Johnstone et al. 1994, Shepherd et al.
1999) but with linear epitopes were able to interact
with the native TSHR. One mAb recognizing TSHR
residues 381–384 showed strong (,80%) blocking
activity at 1ug/ml (Shepherd et al. 1999), which is
pathologically relevant. However, none of the mAbs
had thyroid stimulating activity.
mAbs raised to the native TSHR. Yavin et al. (1981)
claimed the ﬁrst murine mAbs against the TSHR after
immunizing with solubilized thyroid membrane
preparations. While these mAbs may have competed
for labeled TSH binding they were not characterized
as to their concentration or speciﬁcity and appeared to
be against a glycoprotein “component” of the
receptor. Subsequently, Marion et al. (1992)
immunized mice with a puriﬁed TSHR preparation
derived from an immortalized thyroid cell hybridoma
(GEJ) (Karsenty et al. 1985). Among the mAbs
generated, mAb 34A showed binding to TSHRs
expressed on both GEJ and CHO cells and inhibited
labeled TSH binding to such TSHRs. It was also
claimed that 34A stimulated cAMP production
(Marion et al. 1992). Using afﬁnity puriﬁed TSHR
from CHO-TSHR cells Oda et al generated .40
mAbs to the TSHR (Oda et al. 2000). Although they
used the puriﬁed native TSHR as antigen, all the
mAbs bound denatured TSHR produced in bacteria.
However, one mAb (8E3) to residues 381–385 was
active against the intact TSHR in relatively low
concentrations (5ug/ml) as evidenced by strong
(,70%) TSH competing activity. In these studies,
none of the mice became hyperthyroid and no
convincing stimulating mAbs were generated by
these native TSHR immunizations.
mAbs raised against the native TSHR in situ. While
Shimojo et al. (1996) were the ﬁrst to describe a
murine model of hyperthyroid GD, based on
immunization with ﬁbroblasts expressing the TSHR,
no mAbs to the TSHR were produced by this
approach. Costagliola et al. (1998) used genetic
immunization of Balb/c mice with human TSHR
cDNA and induced TSHR-Abs interacting with the
native TSHR, including evidence for the presence of
stimulating TSHR-Abs in their sera. However, the
animals remained euthyroid (Costagliola et al. 1998).
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with conformational determinants.One ofthese mAbs
was utilized to ﬁx the TSHR to a solid phase in second
generation TSH binding competition assay
(Costagliola et al. 1999). An additional blocking
mAb was generated to residues around 382–383
(Costagliola et al. 2002b), which was used to identify
sulfated tyrosine residues involved in TSH–TSHR
interaction (Costagliola et al. 2002b). Subsequently,
these investigators used triple screening of their
hybridomas by FACS, TSH binding competition
and cAMP generation assays and found one IgG mAb
with TSHR stimulating activity (Costagliola et al.
2002a). However, this mAb had an activity that
stimulated cAMP generation by 2–3 times basal at a
concentration of ,300ng/ml (Costagliola et al.
2002a). Using this same genetic immunization
approach and conventional puriﬁed TSHR
immunization, Jeffreys et al. (2002) produced .130
TSHR blocking and neutral mAbs, including many
with TSH competing activity, and used this panel to
locate residues 246–260, 277–296 and 381–385 as
the sites involved in a TSH binding pocket.
By using a TSHR cDNA immunization protocol in
outbred mice ﬁrst reported by Costagliola et al.
(2000), Sanders et al. successfully generated three
stimulating mAbs by screening with TSH competition
assays from those mice which developed TSH
competing activity in their sera (Sanders et al.
2002). These three mAbs had different binding
afﬁnities to the TSHR and different coding sequences
for their variable regions. Signiﬁcant stimulation
(more than 2 £ increases in basal cAMP) was
observed at ,20ng/ml for the most potent mAbs
and at 2ug/ml for the least potent mAb. Importantly,
these three stimulating mAbs showed binding com-
petition with each other and also competed with
TSHR-Abs from patients with GD (Costagliola et al.
1998). This study indicated that the epitopes
recognized by stimulating TSHR-Abs in patients
were similar to those recognized by the stimulating
mAbs raised in mice and were not distributed
heterogeneously on the TSHR a subunit.
A mouse model of GD was also induced by an
adenovirus vector expressing the human TSHR
(Nagayama et al. 2002) and this was reproduced in
the hamster (Ando et al. 2003). By screening with
FACS assays, a panel of hamster TSHR-mAbs were
generated including a stimulating mAb (MS-1) which
increased cAMP production 2 fold with ,20ng/ml
IgG (Ando et al. 2002). Among these mAbs, both
stimulating and blocking varieties showed confor-
mational recognition of the TSHR a subunit (Ando
et al. 2002), but these two epitopes were distinct
(Ando et al. 2004b). Epitope analysis of this panel of
hamster mAbs showed a restricted epitope distri-
bution on the TSHR and this was compatible with the
TSHR-Ab repertoire present in the originating
hamster sera (Ando et al. 2004a). Three mouse
stimulating mAbs (Sanders et al. 2002) shared the
same conformational epitope on the a subunit of the
TSHR as a hamster stimulating mAb (Ando et al.
2004a).
Bioactivity of stimulating TSHR mAbs
Among the stimulating mAbs generated to date, only
one TSHR-mAb (MS-1) has been examined for its
in vivo bioactivity. When injected into mice, MS-1
induced a marked increase in serum thyroid hormones
(Ando et al. 2004b) but mice which were chronically
exposed to oversaturating concentrations of MS-1,
showed a diminution in thyroid hormone output most
likely, secondary to TSHR desensitization and down
regulation as demonstratedinvitro (Ando et al. 2004b).
Hence,thisTSHR-mAbinducedconcentration depen-
dent regulation of TSHR function. Such data may
explain the poor correlation between thyroid function
and serum titers of stimulating antibodies in GD.
The inﬂuence of MS-1 on post-translational
processing of the TSHR has also been studied.
There are constitutive multimeric TSHR complexes
in the cell membrane and TSH is able to induce their
monomerization (Latif et al. 2002). TSH is also able
to enhance intra-molecular cleavage of the TSHR
when assessed by a ﬂow cytometric cleavage assay
(Ando et al. 2002). However, MS-1 stimulation failed
to induce TSHR monomer formation as measured by
the speed of lateral movement of TSHRs after
stimulation (Latif et al. 2004) and failed to enhance
cleavage (Ando et al. 2002). These differences may
have been due to the bivalent nature of MS-1 IgG
since MS-1 Fab was able to act like TSH and increase
the lateral movement of TSHRs and able to accelerate
TSHR cleavage (Latif et al. 2004). These data
indicate signiﬁcant differences in the regulation of
the TSHR by TSH compared to TSHR-Abs
(Table III) and may help to explain the sustained
and prolonged TSHR stimulation seen in patients
with GD.
Summary
There have been many reports of human TSHR-
mAbs in the literature. Only recently, mAbs which
interact with the native TSHR with high afﬁnity have
been generated. These mAbs may block or stimulate
the thyroid glands or may be neutral in their activity
and reveal insights into the antibody repertoire in
autoimmune thyroid disease. Since human TSHR-
mAbs have been difﬁcult to isolate, mAbs from animal
models will continue to be generated as tools to study
the molecular biology of the TSHR. In addition,
TSHR-mAbs have important diagnostic and thera-
peutic potential.
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